Skip to content
Menu
October 7, 2020
OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder
Share this press release:
Document loads below this notification.
×
Dismiss this alert.
Prev
Previous PR
Next PR
Next
Additional Press Releases
March 14, 2023
/
Press Release
Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel
November 30, 2022
/
Press Release
OWP Pharmaceuticals Announces Patent Application for First Oral Liquid Formulation of Trazodone for Treatment of MDD
January 5, 2022
/
Press Release
OWP Pharmaceuticals and EVERSANA Announce Partnership to Commercialize Oral Liquid Formulations to Treat Neuroscience Disorders
View All Press Releases
View All Press Releases
CloseMenu
About Us
Our Purpose
Our People
Leadership Team
Board of Directors
FAQs
Products
Subvenite Starter Kits
Lamotrigine Starter Kits
Roweepra IR
Our Future
Pipeline
News
Press Releases
Events
Connect
Careers
Contact Us
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
© 2023 OWP Pharmaceuticals, Inc., All Rights Reserved.
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer
Cookies
Terms of Use
Privacy
Social Media Policy
Disclaimer